BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29715501)

  • 21. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
    Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
    Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
    Seo S; Suh W
    Mol Vis; 2017; 23():823-831. PubMed ID: 29225458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-angiogenic effect of adiponectin in human primary microvascular and macrovascular endothelial cells.
    Palanisamy K; Nareshkumar RN; Sivagurunathan S; Raman R; Sulochana KN; Chidambaram S
    Microvasc Res; 2019 Mar; 122():136-145. PubMed ID: 30144414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant humanized anti-vascular endothelial growth factor monoclonal antibody efficiently suppresses laser-induced choroidal neovascularization in rhesus monkeys.
    Ji WW; Yu DA; Yang P; Fang P; Cao YX; Li H; Xie N; Yan SS
    Eur J Pharm Sci; 2017 Nov; 109():624-630. PubMed ID: 28916483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept.
    Walker A; Chung CW; Neu M; Burman M; Batuwangala T; Jones G; Tang CM; Steward M; Mullin M; Tournier N; Lewis A; Korczynska J; Chung V; Catchpole I
    J Biol Chem; 2016 Mar; 291(11):5500-5511. PubMed ID: 26728464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-angiogenic effect of KH902 on retinal neovascularization.
    Wang F; Bai Y; Yu W; Han N; Huang L; Zhao M; Zhou A; Zhao M; Li X
    Graefes Arch Clin Exp Ophthalmol; 2013 Sep; 251(9):2131-9. PubMed ID: 23740520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semaphorin 3A blocks the formation of pathologic choroidal neovascularization induced by transforming growth factor beta.
    Bai Y; Liang S; Yu W; Zhao M; Huang L; Zhao M; Li X
    Mol Vis; 2014; 20():1258-70. PubMed ID: 25352735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of VEGF in diseases of the retina].
    Barquet LA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
    Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization.
    Ji L; Waduge P; Hao L; Kaur A; Wan W; Wu Y; Tian H; Zhang J; Webster KA; Li W
    FASEB J; 2022 Jan; 36(1):e22106. PubMed ID: 34918375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Sema3C Mutant Resistant to Cleavage by Furin (FR-Sema3C) Inhibits Choroidal Neovascularization.
    Toledano S; Lu H; Palacio A; Ziv K; Kessler O; Schaal S; Neufeld G; Barak Y
    PLoS One; 2016; 11(12):e0168122. PubMed ID: 28036336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina.
    Balser C; Wolf A; Herb M; Langmann T
    J Neuroinflammation; 2019 Feb; 16(1):26. PubMed ID: 30732627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X; Sun X
    Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD.
    Wei X; Zhang T; Yao Y; Zeng S; Li M; Xiang H; Zhao C; Cao G; Li M; Wan R; Yang P; Yang J
    Exp Eye Res; 2018 Mar; 168():2-11. PubMed ID: 29284110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
    Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
    Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y; Tan CS
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knockout of αA-crystallin inhibits ocular neovascularization.
    Xu Q; Bai Y; Huang L; Zhou P; Yu W; Zhao M
    Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):816-26. PubMed ID: 25574047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DS-7080a, a Selective Anti-ROBO4 Antibody, Shows Anti-Angiogenic Efficacy with Distinctly Different Profiles from Anti-VEGF Agents.
    Isumi Y; Hayashi S; Inoue T; Yoshigae Y; Sato T; Hasegawa J; Agatsuma T
    Transl Vis Sci Technol; 2020 Aug; 9(9):7. PubMed ID: 32879763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.